Low-Grade Brain Tumors: Treatment Outcomes in Argentina
Part of Brain & nervous system, Cancer clinical trials.
This study follows adults with low-grade gliomas (slow-growing brain tumors) to understand how often they occur, how long patients survive, and which treatments work best. Researchers will review medical records to learn more about care options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a confirmed diagnosis of low-grade glioma (WHO grade I or II brain tumor)
- Your diagnosis was confirmed by tissue biopsy and genetic testing
- You receive care at Hospital Italiano de Buenos Aires or are affiliated with their health plan
- Your medical records show at least 1 year of documented follow-up during the study period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a personalized, computer-guided way to plan proton beam radiation for adults with low-grade glioma. The goal is to see if the approach is feasible and can improve how treatment is planned.
This study is looking at whether a simple blood test that checks for tiny molecules (called miRNAs) can help monitor people with slow-growing brain tumors. If you had surgery for a grade 2 or 3 glioma at Caen University Hospital and are still being followed there, this study might be for you.
This study offers cognitive rehabilitation and long-term monitoring for adults with lower grade gliomas. It aims to help improve thinking and memory problems you may be experiencing.
This study records health details about adults who may have a low-grade glioma (a slower-growing brain tumor) based on scan results. Researchers use these data to better understand disease patterns and outcomes, and help connect individual patients to future research.
This study asks patients with a specific type of low-grade brain tumor (IDH mutant grade 2 glioma) to share their experiences and quality of life while receiving a treatment called vorasidenib, with or without radiation. Your feedback helps doctors understand how well the treatment works from your perspective.
This study looks at how different treatments and patient factors affect outcomes in people with glioblastoma, an aggressive type of brain tumor. By joining, you help researchers learn which approaches work best, which could improve care for future patients.
Hear when a new Low-grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.